Retinoblastoma management in China: clinical challenges
- PMID: 41280625
- PMCID: PMC12635816
- DOI: 10.18240/ijo.2025.12.21
Retinoblastoma management in China: clinical challenges
Abstract
Retinoblastoma (RB) is the most common intraocular malignancy in children. In recent years, advancements in chemotherapy-based comprehensive treatment approaches and diagnostic technologies have significantly improved long-term survival rates, shifting treatment goals from saving lives toward preserving vision and enhancing quality of life. In major RB treatment centers in China, survival rates have reached levels comparable to those in developed countries. However, in some underdeveloped regions, RB continues to pose a serious threat to affected children. To further improve survival rates and quality of life for RB patients and their families in China, a series of essential measures should be implemented. These include strengthening public education to raise awareness of RB, enhancing diagnostic efficiency, promoting standardized treatment protocols, providing genetic counseling and prenatal assessment for high-risk populations, and fostering the training of specialized healthcare professionals.
Keywords: chemotherapy; clinical management; retinoblastoma.
International Journal of Ophthalmology Press.
Conflict of interest statement
Conflicts of Interest: Wang N, None; Ke F, None; Li J, None; Xu LY, None; Wang TY, None; Ma JM, None.
References
-
- Finger PT, Tomar AS. Retinoblastoma outcomes: a global perspective. Lancet Glob Health. 2022;10(3):e307–e308. - PubMed
-
- Zhang Y, Wang YZ, Shi JT, et al. Clinical analysis of 2790 children with retinoblastoma: a single-center experience in China. World J Pediatr. 2023;19(12):1169–1180. - PubMed
-
- Zhou CD, Wen XY, Ding Y, et al. Eye-preserving therapies for advanced retinoblastoma: a multicenter cohort of 1678 patients in China. Ophthalmology. 2022;129(2):209–219. - PubMed